BPCE
RXRX icon

Bank Pictet & Cie (Europe)’s Recursion Pharmaceuticals RXRX Stock Holding History

Bank Pictet & Cie (Europe)’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,630,000
Closed -$7.95M – 208
2025
Q3 		$7.95M Buy
+1,630,000
New +$8.56M 0.16% 78

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bank Pictet & Cie (Europe)'s RXRX Position: Q4 2025 in Review

Bank Pictet & Cie (Europe) sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 1,630,000 shares — an estimated $7.95M sold.

Bank Pictet & Cie (Europe) first reported a position in RXRX in Q3 2025 and held it in 1 quarter. The position peaked at $7.95M in Q3 2025. 332 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

  • Bank Pictet & Cie (Europe) reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Bank Pictet & Cie (Europe) sold 1,630,000 Recursion Pharmaceuticals shares in Q4 2025, an estimated $7.95M.
  • Bank Pictet & Cie (Europe) first reported a position in Recursion Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Bank Pictet & Cie (Europe)'s Recursion Pharmaceuticals position peaked at $7.95M in Q3 2025.
  • 332 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Bank Pictet & Cie (Europe)'s 13F filing for Q4 2025, filed 16 Jan 2026.